Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms

Acta Pharmacologica Sinica

Volumn 34, Issue 7, 2013, Pages 939-950

  Peng, Yan Min ^a   Zheng, Jian Bin ^b   Zhou, Yu Bo ^a   Li, Jia ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

anticancer agent; curcumin; HeLa cell; high throughput screen; mitochondria; NF B; P1; ROS

Indexed keywords

CURCUMIN; DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; SULFORHODAMINE B; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN HEK293; FLUORESCENCE ACTIVATED CELL SORTING; HELA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; MITOCHONDRION; OXYGEN CONSUMPTION; PLASMID; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HELA CELLS; HUMANS; NF-KAPPA B; PROTEIN BINDING; SIGNAL TRANSDUCTION; TROPANES;

EID: 84881433063     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.2     Document Type: Article

References (57)

1. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-81.
2. Yakovlev VA, Barani IJ, Rabender CS, Stephen M, Leach JK, Graves PR, et al. Tyrosine nitration of IκBα: a novel mechanism for NF-κB activation. Biochemistry 2007; 46: 11671-83.
3. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 2004; 13: 1327-38.
4. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kB: its role in health and disease. J Mol Med 2004; 82: 434-48.
5. Strnad J, Burke JR. IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol Sci 2007; 28: 142-8.
6. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-8.
7. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008; 68: 1443-50.
8. Lejeune FJ, Rüegg C, Liénard D. Clinical applications of TNF-α in cancer. Curr Opin Immunol 1998; 10: 573-80.
9. Flier JS, Underhill LH, Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25.
10. Mocellin S, Pilati P, Nitti D. Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr Pharm Des 2007; 13: 537-51.
11. Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med 1991; 57: 1-7.
12. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
13. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G85-G95.
14. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-9.
15. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem Pharmacol 2001; 62: 1433-8.
16. Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 1992; 17: 77-83.
17. Azuine MA, Bhide SV. Protective single/combined treatment with betel leaf and turmeric against methyl (acetoxymethyl) nitrosamineinduced hamster oral carcinogenesis. J Cancer Res Clin Oncol 1992; 51: 412-5.
18. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005; 223: 181-90.
19. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-[kappa] B activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70: 700-13.
20. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-[kappa] B activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 2007; 73: 1434-45.
21. Kudo C, Yamakoshi H, Sato A, Ohori H, Ishioka C, Iwabuchi Y, et al. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma. Anticancer Res 2011; 31: 3719-26.
22. Mosley CA, Liotta DC, Snyder JP. Highly active anticancer curcumin analogues. Adv Exp Med Biol 2007; 595: 77-103.
23. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB regulated gene products. Cancer Res 2007; 67: 3853-61.
24. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5: 2563-71.
25. Zang Y, Yu LF, Pang T, Fang LP, Feng X, Wen TQ, et al. AICAR induces astroglial differentiation of neural stem cells via activating the JAK/ STAT3 pathway independently of AMP-Activated protein kinase. J Biol Chem 2008; 283: 6201-8.
26. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1: 1112-6.
27. Du JQ, Wu J, Zhang HJ, Zhang YH, Qiu BY, Wu F, et al. Isoquinoline-1, 3,4-trione derivatives inactivate caspase-3 by generation of reactive oxygen species. J Biol Chem 2008; 283: 30205-15.
28. Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N. Nuclear transport impairment of amyotrophic lateral sclerosis linked mutations in FUS/ TLS. Ann Neurol 2011; 69: 152-62.
29. Ogura A, Oowada S, Kon Y, Hirayama A, Yasui H, Meike S, et al. Redox regulation in radiation-induced cytochrome c release from mitochondria of human lung carcinoma A549 cells. Cancer Lett 2009; 277: 64-71.
30. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NFkappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
31. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, et al. Inhibition of IKK-NF-κB signaling pathway by EF24, a novel monoketone analogue of curcumin. Mol Pharmacol 2008; 3: 654-61.
32. Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, et al. Curcumin analog GO-Y030 is a novel inhibitor of IKK-β that suppresses NF-κβ signaling and induces apoptosis. Cancer Sci 2011; 102: 1045-51.
33. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007; 12: 913-22.
34. Pilati P, Rossi CR, Mocellin S. Strategies to enhance the anticancer potential of TNF. Front Biosci 2008; 13: 3181-93.
35. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
36. Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, et al. The curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis. Cancer Sci 2011; 102: 1045-51.
37. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri Fr, et al. Inhibition of IKK-NF-κB signaling pathway by EF24, a novel monoketone analogue of curcumin. Mol Pharmacol 2008; 3: 654-61.
38. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BVV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999; 456: 311-4.
39. Galati G, Sabzevari O, Wilson JX, O'Brien PJ. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002; 177: 91-104.
40. Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-Activated protein kinase pathway. Mol Pharmacol 2008; 73: 1491-501.
41. Singh U, Barik A, Singh BG, Priyadarsini KI. Reactions of reactive oxygen species (ROS) with curcumin analogues: structure-Activity relationship. Free Radic Res 2011: 3: 1-9.
42. Tan X, Sidell N, Mancini A, Huang RP, Wang S, Horowitz IR, et al. Multiple anticancer activities of ef24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod Sci 2010; 17: 931-40.
43. Gloire G, Legrand-Poels S, Piette J. NF-[kappa] B activation by reactive oxygen species: fifteen years later. Biochem pharmacol 2006; 72: 1493-505.
44. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. Adv Exp Med Biol 1996; 387: 63-8.
45. Staal FJ, Roederer M, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci U S A 1990; 87: 9943-7.
46. Loukili N, Rosenblatt-Velin N, Rolli J, Levrand S, Feihl F, Waeber B, et al. Oxidants positively or negatively regulate nuclear factor κB in a context-dependent manner. J Biol Chem 2010; 285: 15746-52.
47. Song YS, Lee YS, Chan PH. Oxidative stress transiently decreases the IKK complex (IKKα, β, and γ), an upstream component of NF-κB signaling, after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005; 25: 1301-11.
48. Zhang Y, Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-κB (NF-κB) and c-Jun NH2-terminal kinase (JNK). Cancer Res 2004; 64: 1902.
49. Matthews JR, Kaszubska W, Turcatti G, Wells TNC, Hay RT. Role of cysteine62 in DNA recognition by the P50 subunit of NF-κB. Nucleic Acids Res 1993; 21: 1727.
50. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 1992; 20: 3821-30.
51. Tjalkens RB, Luckey SW, Kroll DJ, Petersen DR. [alpha],[beta]-Unsaturated aldehydes increase glutathione s-transferase mRNA and protein: Correlation with activation of the antioxidant response element. Arch Biochem Biophys 1998; 359: 42-50.
52. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
53. Koliopanos A, Avgerinos C, Paraskeva C, Touloumis Z, Kelgiorgi D, Dervenis C. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008; 7: 345-56.
54. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosis. Blood 2008; 111: 4880-91.
55. Vince JE, Wong W, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNF [alpha]-dependent apoptosis. Cell 2007; 131: 682-93.
56. Zhang Y, Gavriil M, Lucas J, Mandiyan S, Follettie M, Diesl V, et al. IκBα kinase inhibitor IKI-1 conferred tumor necrosis factor a sensitivity to pancreatic cancer cells and a xenograft tumor model. Cancer Res 2008; 68: 9519-24.
57. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto-β- boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol 2006; 176: 3127-40.